Free Trial

Spyre Therapeutics Q4 2023 Earnings Report

Spyre Therapeutics logo
$25.49 +0.23 (+0.91%)
(As of 12:46 PM ET)

Spyre Therapeutics EPS Results

Actual EPS
-$2.28
Consensus EPS
-$0.48
Beat/Miss
Missed by -$1.80
One Year Ago EPS
N/A

Spyre Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Spyre Therapeutics Announcement Details

Quarter
Q4 2023
Time
N/A
URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Register for the FREE Workshop Now & get $10 in Bitcoin

Spyre Therapeutics Earnings Headlines

Spyre Therapeutics Added to the Nasdaq Biotechnology Index
Forbes rich list released… #1 to be assassinated?
Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.
Spyre Therapeutics: Different Name, Same Tune
See More Spyre Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Spyre Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spyre Therapeutics and other key companies, straight to your email.

About Spyre Therapeutics

Spyre Therapeutics (NASDAQ:SYRE), a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

View Spyre Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings